Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × Paclitaxel × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 107 Breast Neoplasms 96 Ovarian Neoplasms 56 Triple Negative Breast Neoplasms 48 Squamous Cell Carcinoma of Head and Neck 38 Fallopian Tube Neoplasms 36 Lung Neoplasms 35 Endometrial Neoplasms 35 Neoplasms 26 Neoplasm Metastasis 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 24 Stomach Neoplasms 23 Esophageal Neoplasms 21 Esophageal Squamous Cell Carcinoma 17 Uterine Cervical Neoplasms 14 Head and Neck Neoplasms 14 Colorectal Neoplasms 13 Carcinoma 13 Carcinoma, Ovarian Epithelial 12 Carcinoma, Squamous Cell 10 Small Cell Lung Carcinoma 9 Urinary Bladder Neoplasms 8 Adenocarcinoma Of Esophagus 8 Oropharyngeal Neoplasms 7 Melanoma 7 Carcinoma, Transitional Cell 7 Pancreatic Neoplasms 6 Mouth Neoplasms 6 Inflammatory Breast Neoplasms 6 Adenocarcinoma 6

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡